Clearside Biomedical’s (CLSD) Outperform Rating Reaffirmed at Wedbush
Clearside Biomedical Inc. (NASDAQ:CLSD)‘s stock had its “outperform” rating reiterated by equities researchers at Wedbush in a note issued to investors on Wednesday. They currently have a $28.00 price target on the stock. Wedbush’s target price points to a potential upside of 28.09% from the stock’s current price.
A number of other analysts have also recently weighed in on the stock. Zacks Investment Research upgraded shares of Clearside Biomedical from a “sell” rating to a “hold” rating in a research note on Monday, September 19th. Stifel Nicolaus initiated coverage on shares of Clearside Biomedical in a research note on Monday, June 27th. They issued a “buy” rating and a $13.00 price objective for the company. Needham & Company LLC initiated coverage on shares of Clearside Biomedical in a research report on Tuesday, June 28th. They set a “buy” rating and a $16.00 target price on the stock. Finally, Cowen and Company initiated coverage on shares of Clearside Biomedical in a research report on Monday, June 27th. They set an “outperform” rating on the stock. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Clearside Biomedical has an average rating of “Buy” and a consensus target price of $16.19.
Clearside Biomedical (NASDAQ:CLSD) traded down 3.98% during midday trading on Wednesday, reaching $20.99. 27,898 shares of the company were exchanged. The firm’s 50-day moving average is $14.20 and its 200-day moving average is $9.48. Clearside Biomedical has a one year low of $5.65 and a one year high of $25.08. The firm’s market cap is $431.24 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/19/clearside-biomedicals-clsd-outperform-rating-reaffirmed-at-wedbush.html
Clearside Biomedical (NASDAQ:CLSD) last issued its quarterly earnings data on Thursday, August 11th. The company reported ($0.62) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.32) by $0.30. On average, equities analysts expect that Clearside Biomedical will post ($2.10) EPS for the current fiscal year.
A number of institutional investors have recently made changes to their positions in the company. AWM Investment Company Inc. bought a new position in shares of Clearside Biomedical during the second quarter worth about $350,000. Iguana Healthcare Management LLC acquired a new stake in shares of Clearside Biomedical during the second quarter valued at about $526,000. Marshall Wace LLP acquired a new stake in shares of Clearside Biomedical during the second quarter valued at about $1,122,000. Finally, Perceptive Advisors LLC acquired a new stake in shares of Clearside Biomedical during the second quarter valued at about $4,450,000. 36.61% of the stock is currently owned by institutional investors and hedge funds.
Clearside Biomedical Company Profile
Clearside Biomedical, Inc is a late-stage clinical biopharmaceutical company. The Company is developing drug therapies to treat blinding diseases of the eye. The Company’s product candidates are focused on diseases affecting the retina and choroid, especially diseases associated with macular edema, and are injected into the suprachoroidal space (SCS) adjacent to the choroid, using its SCS Microinjector.
Receive News & Ratings for Clearside Biomedical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.